摘要
目的探讨胺碘酮联合美西律对冠心病心律失常患者QT离散度、 QRS时限的影响。方法选取2018年1月至2019年6月我院收治的冠心病心律失常患者188例,分为对照组(90例,美西律)和观察组(98例,胺碘酮联合美西律)。治疗3周后,比较两组的QT离散度、 QRS时限及不良反应发生率。结果治疗后,两组的QT离散度低于治疗前,QRS时限短于治疗前(P <0.05);观察组的QT离散度低于对照组,QRS时限短于对照组(P <0.05)。观察组的不良反应发生率为5.10%,与对的7.78%比较差异无统计学意义(P>0.05)。结论胺碘酮联合美西律治疗冠心病心律失常患者可有效降低其QT离散度,缩短QRS时限,且安全性较高,值得临床推广。
Objective To explore the influence of amiodarone combined with mexiletine on QT dispersion and QRS time limit in patients with coronary heart disease and arrhythmia.Methods 188 patients with coronary heart disease and arrhythmia admitted to our hospital from January 2018 to June 2019 were selected and divided into control group(90 cases,mexiletine)and observation group(98 cases,amiodarone combined with mexiletine).After 3 weeks of treatment,the QT dispersion,QRS time limit,and incidence of adverse reactions were compared between the two groups.Results After treatment,the QT dispersion of the two groups were lower than those before treatment,and the QRS time limit were shorter than those before treatment(P<0.05);The QT dispersion of the observation group was lower than that of the control group,and the QRS time limit was shorter than that of the control group(P<0.05).The incidence of adverse reactions in the observation group was 5.10%,which had no statistical difference with 7.78%in the control group(P>0.05).Conclusions Amiodarone combined with mexiletine in the treatment of patients with coronary heart disease and arrhythmia can effectively reduce the QT dispersion,shorten the QRS time limit,with higher safety,which is worthy of clinical promotion.
作者
段班林
何梓伟
罗芬
DUAN Banlin;HE Ziwei;LUO Fen(Department of Cardiology,the People's Hospital of Qujiang District,Shaoguan 512100,China)
出处
《临床医学工程》
2020年第11期1511-1512,共2页
Clinical Medicine & Engineering
关键词
冠心病心律失常
胺碘酮
美西律
QT离散度
QRS时限
不良反应
Coronary heart disease and arrhythmia
Amiodarone
Mexiletine
QT dispersion
QRS time limit
Adverse reaction
